GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2025 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 4% Year-Over-Year to $6.9 billion Biktarvy Sales Increased 9$3.5 billion Foster City, CA, August 7, 2025 - Gilead Sciences, Inc. (Nasdaq: GILD) announced today its second quarter 2025 results of operations. "This was a very successful second quarter for Gilead, including the FDA approval for Yeztugo as the world's first twice-yearly HIV prevention option," said Daniel O'Day, Gilead's ...